nach oben

Clinical Research in Cardiology

Erschienen in:

01.01.2014 | Original Paper

Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis

verfasst von: Yvonne P. Clever, Bodo Cremers, Wolfgang von Scheidt, Michael Böhm, Ulrich Speck, Bruno Scheller

Erschienen in: Clinical Research in Cardiology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

Treatment of coronary in-stent restenosis (ISR) remains a challenge in interventional cardiology, especially after drug eluting stent (DES)-ISR. Drug coated balloons (DCB) provide a new therapeutic option in the treatment of ISR. In patients with multiple layers of stents due to refractory ISR and exclusion criteria for revascularization by coronary artery bypass grafting, DCB may be a last therapy option. This paper presents DCB therapy as compassionate use treatment before the balloons were available in Europe.

Patients

Compassionate use of DCB was approved by the local ethical committee. Fifteen patients with refractory ISR in 28 lesions were prospectively enrolled between 12/2006 and 04/2009. The frequency of prior ISR was 3.0 ± 1.1. Nine patients presented with coronary three-vessel disease and six patients with one- or two-vessel disease. Thirteen patients had DES-ISR, two patients with contraindication for prolonged dual anti-platelet therapy repeated BMS-ISR. Two or three layers of metal were present in eleven patients. Four patients had prior coronary artery bypass grafting.

Results

All lesions were treated with DCB (SeQuent™ Please, B.Braun, Germany). Angiographic follow-up was obtained in 14 patients. Clinical follow-up was available in all patients after 3.2 ± 0.8 years (maximum 4.8 years). Target lesion revascularization was done in 2 of 28 lesions (7.1 %), one patient with ischemic cardiomyopathy died after 1.5 years. No further MACE occurred.

Conclusion

DCB appear to be safe and clinically useful in the treatment of ISR. DCB is a new promising option for high-risk patients with refractory ISR.

Gruntzig A (1978) Transluminal dilatation of coronary-artery stenosis. Lancet 1:263PubMedCrossRef

Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701–706PubMedCrossRef

Morice MC, Serruys PW, Sousa JE et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780PubMedCrossRef

Kastrati A, Mehilli J, Pache J et al (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039PubMedCrossRef

Stone GW, Moses JW, Ellis SG et al (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008PubMedCrossRef

Virmani R, Guagliumi G, Farb A et al (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705PubMedCrossRef

Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202PubMedCrossRef

Iakovou I, Schmidt T, Bonizzoni E et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef

Pfisterer M, Brunner-La Rocca HP, Buser PT (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584–2591PubMedCrossRef

10.

Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029PubMedCrossRef

11.

Daemen J, Wenaweser P, Tsuchida K et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678PubMedCrossRef

12.

Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997PubMedCrossRef

13.

Kastrati A, Mehilli J, von Beckerath N et al (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293:165–171PubMedCrossRef

14.

Mehilli J, Byrne RA, Tiroch K et al (2010) Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 55:2710–2716PubMedCrossRef

15.

Cosgrave J, Melzi G, Corbett S et al (2007) Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 153:354–359PubMedCrossRef

16.

Airoldi F, Briguori C, Iakovou I et al (2006) Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J cardiol 97:1182–1187PubMedCrossRef

17.

Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G (2004) Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810–814PubMedCrossRef

18.

Speck U, Scheller B, Abramjuk C et al (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240:411–418PubMedCrossRef

19.

Cremers B, Speck U, Kaufels N et al (2009) Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 101:201–206PubMed

20.

Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B (2009) Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 98:325–330PubMedCrossRef

21.

Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B (2007) Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol 42:579–585PubMedCrossRef

22.

Wohrle J, Birkemeyer R, Markovic S et al (2011) Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97:1338–1342PubMedCrossRef

23.

Rittger H, Brachmann J, Sinha AM et al (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 59:1377–1382PubMedCrossRef

24.

Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124PubMedCrossRef

25.

Scheller B, Hehrlein C, Bocksch W et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781PubMedCrossRef

26.

Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994PubMedCrossRef

27.

Unverdorben M, Kleber FX, Heuer H et al (2010) Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 99:165–174PubMedCrossRef

28.

Habara S, Mitsudo K, Kadota K et al (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovascular interventions 4:149–154PubMedCrossRef

29.

Ali RM, Degenhardt R, Zambahari R et al (2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 7(Suppl K):K83–K92PubMedCrossRef

30.

Scheller B, Clever YP, Kelsch B et al (2012) Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovascular interventions 5:323–330PubMedCrossRef

31.

Tepe G, Zeller T, Albrecht T et al (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358:689–699PubMedCrossRef

32.

Werk M, Langner S, Reinkensmeier B et al (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118:1358–1365PubMedCrossRef

33.

Navarese EP, Austin D, Gurbel PA et al (2013) Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res cardiol 102:279–287PubMedCentralPubMedCrossRef

34.

Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 31:2501–2555PubMedCrossRef

35.

Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef

36.

Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151:1260–1264PubMedCrossRef

37.

Waksman R, Bhargava B, White RL et al (1999) Intracoronary radiation for patients with refractory in-stent restenosis: an analysis from the WRIST-crossover trial. Washington Radiation for In-stent Restenosis Trial. Cardiovasc Radiat Med 1:317–322PubMedCrossRef

38.

Waksman R (2012) Too early to call. Cardiovasc Revasc Med 13:157–158PubMedCrossRef

39.

Alfonso F, Perez-Vizcayno MJ, Dutary J et al (2012) Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis: results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv 5:728–737PubMedCrossRef

40.

Alli OO, Teirstein PS, Satler L et al (2012) Five-year follow-up of the sirolimus-eluting stents vs vascular brachytherapy for bare metal in-stent restenosis (SISR) trial. Am Heart J 163:438–445PubMedCrossRef

41.

Raber L, Magro M, Stefanini GG et al (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125:1110–1121PubMedCrossRef

42.

Iofina E, Langenberg R, Blindt R, Kuhl H, Kelm M, Hoffmann R (2006) Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 98:1022–1027PubMedCrossRef

43.

Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H (2006) Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 58:665–672PubMedCrossRef

44.

Scheller B, Speck U, Romeike B et al (2003) Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24:1462–1467PubMedCrossRef

45.

Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G (2003) Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42:1415–1420PubMedCrossRef

46.

Speck U, Cremers B, Kelsch B et al (2012) Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 5:392–400PubMedCrossRef

47.

Scheller B (2011) Opportunities and limitations of drug-coated balloons in interventional therapies. Herz 36:232–240PubMedCrossRef

48.

Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX (2011) Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 7:K61–K65PubMedCrossRef

49.

Wöhrle J, Zadura M, Möbius-Winkler S et al (2012) SeQuent please world wide registry: clinical results of SeQuent please paclitaxel coated balloon angioplasty in a large-scaled, prospective registry study. J Am Coll Cardiol 60(18):1733–1738PubMedCrossRef

50.

Vajda Z, Guthe T, Perez MA et al (2011) Neurovascular in-stent stenoses: treatment with conventional and drug-eluting balloons. AJNR 32:7–1942CrossRef

51.

Bonaventura K, Leber AW, Sohns C et al (2012) Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol 101:573–584PubMedCrossRef

52.

Dorenkamp M, Boldt J, Leber A et al (2013) Cost-Effectiveness of Paclitaxel-Coated balloon angioplasty in patients with Drug-Eluting stent restenosis. Clin Cardiol 36(7):407–413PubMedCrossRef

53.

Cassese S, Byrne RA, Ott I et al (2012) Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv 5:582–589PubMedCrossRef

Titel: Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis
verfasst von: Yvonne P. Clever
Bodo Cremers
Wolfgang von Scheidt
Michael Böhm
Ulrich Speck
Bruno Scheller
Publikationsdatum: 01.01.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 1/2014
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0617-7

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis

Abstract

Objective

Patients

Results

Conclusion

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Patients

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Epidemiology of Chagas disease in Europe: many calculations, little knowledge

Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease

Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis

Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging

Reported underuse of risk scores in patients with acute coronary syndromes without persistent ST elevations in clinical practice: results of a survey of the ALKK study group

Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie